The Patient-Reported Outcomes Measurement Information System (PROMIS) was a National Institutes of Healthfunded initiative to develop measures of symptoms and function. Responsiveness is the degree to which a measure can detect underlying changes over time. The objective of the current study was to document the responsiveness of 8 PROMIS measures in a large, population-based cancer cohort. METHODS: The Measuring Your Health study recruited 2968 patients who were diagnosed with 1 of 7 cancers between 2010 and 2012 through 4 Surveillance, Epidemiology, and End Results registries. Participants completed a baseline survey (6-13 months after diagnosis) and a 6-month follow-up survey. Changes in 8 PROMIS scores were compared with global ratings of transition, changes in performance status, and clinical events. RESULTS: Measures were responsive to 6-month declines and improvements in performance status with small to large effect sizes (ES) (Cohen d 5 0.34-0.71; P <.01). Mean changes and effect sizes were larger for participants who reported declines compared with those who reported improvements. Small-to-medium ES were observed in patients who reported being "a little" worse (d 5 0.31-0.56), and medium-to-large ES were observed in those who reported being "a lot" worse (d 5 0.53-0.72). Hospitalized participants reported significant score increases, resulting in worsening of pain (d 5 0.51), fatigue (d 5 0.35), and depression (d 5 0.57; all P <.01). Cancer recurrence and progression were associated with smaller increases in pain, fatigue, and sleep disturbance (d 5 0.22-0.27). CONCLUSIONS: The current results indicated that all 8 PROMIS measures were sensitive to patient-perceived worsening and improvement and to major clinical events. These findings will be able to inform the design and interpretation of future research studies and clinical initiatives administering PROMIS measures. Cancer 2017;123:327-35.
INTRODUCTION
Patient-reported outcomes (PROs) are measures of functioning and well-being in physical, mental and social spheres of health. 1 In 2004, the National Institutes of Health (NIH) launched the Patient-Reported Outcomes Measurement Information System (PROMIS) as part of an NIH Roadmap (and, later, an NIH Common Fund) initiative assessing all disease and health areas. 2, 3 PROMIS was designed using extensive qualitative and quantitative methods to develop a comprehensive set of item banks and short-form measures.
Responsiveness is an important aspect of scale evaluation for determining the degree to which a PRO measure can detect underlying true changes. 4 Anchors used as indicators of change include patient transition reports and documented clinical events over the study period. To date, only a few studies have been published examining the responsiveness of PROMIS measures. [5] [6] [7] One study examined PROMIS responsiveness and minimally important differences in a clinic-based sample of patients with advanced-stage cancer (n 5 101). 8 Our current study builds on these findings, evaluating the responsiveness of 8 PROMIS short-form measures in the Measuring Your Health (MY-Health) Study. 9 MYHealth was designed to conduct a large-scale psychometric evaluation of PROMIS measures across a diverse cancer sample 10 using community-based sampling to represent the full range of known health disparities across age and race/ethnic groups. 11 This study presents an ideal environment for evaluating responsiveness in a large sample of patients with 7 different cancers, providing 6-month prospective data and capturing both patient and clinical indicators. Demonstrating responsiveness in this heterogeneous cohort of patients with cancer will support using PROMIS measures in population-based studies, comparative effectiveness research, clinical trials, and other longitudinal studies.
MATERIALS AND METHODS

Study Sample and Data-Collection Procedures
We recruited patients with Cancer as part of the MYHealth study. Four population-based cancer registries, which are part of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program in 3 states (California, Louisiana, and New Jersey), identified participants within 6 to 13 months after they were diagnosed with primary colorectal cancer, lung cancer, non-Hodgkin lymphoma, breast cancer, gynecologic (uterine, cervical) cancer, or prostate cancer. We oversampled by younger age (ages 21-49 and 50-64 years) and nonwhite race/ethnicity (Hispanic, black, and Asian), targeting 20% of the full sample represented (n 5 1000) in each group. Enrolled participants completed a paper baseline survey and a 6-month follow-up survey. Among participants who completed our follow-up survey, we conducted a medical record abstraction (MRA) of cancer-related procedures, hospitalizations, and medical events for a random subsample. Further details on study design, eligibility, and baseline data-collection procedures have been described in depth elsewhere. 12 Trained SEER study abstractors conducted an MRA on a 40% subsample of participants who completed both baseline and follow-up surveys. Patients with stage III and IV cancer were oversampled to ensure that this group had sufficient events for evaluation between the baseline and follow-up surveys. Abstractors reviewed hospital and outpatient records for cancer-related treatment (chemotherapy, hormone therapy, targeted therapies, radiation, and surgical procedures), hospitalizations, medical events, cancer status (recurrence, progression, remission), and vital status.
Clinical and Survey Variables
Data on the date of cancer diagnosis, cancer type, and cancer stage were obtained from routine SEER registry databases. Cancer stage was defined using American Joint Commission on Cancer criteria. Information on hospitalization (dates) and documented cancer status change (type and date of change: remission, recurrence, progression, missing) was collected through medical record review. The participant baseline survey collected the patient-reported demographic and clinical information (surgery, radiation, chemotherapy, hormone therapy) used in this study, including age, race/ethnicity, education level, and birthplace (United States or outside the United States). The race/ethnicity categories (non-Hispanic white [white], black, Hispanic, Asian) used for analysis were created following US Census (2010) classification algorithms. 13 When self-reported race/ethnicity was missing, we used information from the SEER registry database (<0.4% of participants).
Two non-PROMIS PRO measures were collected at both baseline and follow-up to examine PROMIS 6-month responsiveness: 1) the 7-item Functional Assessment of Cancer Treatment-General (FACT-G) Physical Well Being subscale (the full measure was not administered because of the overall survey length); 14 and 2) the single-item, patient self-report Eastern Cooperative Oncology Group performance status (ECOG PS) scale, which is often used in cancer clinical trials to assess disease impact on activities of daily living. 15 The ECOG PS scale has 5 response options ranging from "normal activity without symptoms" to "unable to get out of bed."
Main Outcome Measures
We created 8 PROMIS measures administered at baseline and follow-up time points: physical function (15 items), fatigue (14 items), pain interference (11 items), anxiety (11 items), depression (10 items), ability to participate in social roles version 2 (social function; 10 items), cognitive function version 2 (8 items), and sleep disturbance (8 items). 16, 17 Each measure is a custom short form that was created for the MY-Health Study. These measures were designed to include multiple "off-the-shelf" PROMIS short forms as well as frequent computer adaptive testing selections for lower functioning patients (0.5 and 1.0 standard deviations below the US population mean).
On the follow-up survey, a single-item patientreported global rating of change was administered immediately after each of the 8 PROMIS measures. 18 This global change item asked the following: "Compared with 6 months ago, how is your (PROMIS symptom or function) now?" Two different response sets were used: 1) responses to pain, fatigue, and anxiety of "a lot less," "a little less," "about the same," "a little more," or "a lot more"; and 2) responses to physical function, social function, cognitive function, depression (labeled "feelings"), and sleep disturbance (labeled "sleep quality") of "a lot better," "a little better," "about the same," "a little worse," or "a lot worse."
Statistical Analyses
First, we evaluated our follow-up survey completion rate, examining demographic and clinical differences compared with the full baseline sample. Then, we conducted descriptive analyses of our sample to examine the 6-month change between our baseline and follow-up surveys for each PROMIS measure. We calculated means, standard deviations, and effect sizes for baseline and follow-up mean scores. Unadjusted change scores (baseline and 6-months scores) were evaluated within each anchor response option (self-reported measures of 6-month change) for each PROMIS measure.
We evaluated 6-month responsiveness across the 8 PROMIS measures using retrospective ratings of global change. Retrospective anchors were collected using selfreported 5-point global change ratings corresponding to each PROMIS domain measure. For each PROMIS measure, we calculated the mean score change and effect size across each change rating (eg, "a lot better").
We analyzed prospective change using 5 knowngroup contrasts based on both survey self-report (ECOG PS and current cancer status) and medical record information (the number of hospitalizations and recurrences/ progressions vs remissions). Each comparison examined relative mean score differences between a group for which change was expected versus a stable contrast group for which no expected change was anticipated. We also evaluated Spearman rank-order correlations (r) of change for PROMIS measures (selected with baseline correlations above r 5 0.7: Pain, Fatigue, Social Function, and Physical Function) using with the FACT Physical Well Being subscale.
We calculated the effect sizes of all responsiveness calculations by dividing the absolute value of the mean 6-month change in each PROMIS score by the baseline standard deviation, reported as the absolute value. We applied the Cohen interpretation of effect size for magnitude (Cohen d . 19 Past studies suggest that change scores of approximately d 5 0.2 are probably too low to be classified as an estimate of clinically meaningful change. 18, 20, 21 Therefore, we considered values at or above d 5 0.3 as clinically meaningful change. We used the SAS version 9.4 statistical software package (SAS Institute Inc, Cary, NC).
RESULTS
The overall follow-up survey response rate was 54%. Participants who completed the follow-up survey were more likely to be non-Hispanic whites (62%), aged 65 years (57%), or to report a college degree or higher (62%). Patient with prostate cancer had the highest follow-up rates (61%), and those with cervical cancer had lowest (34%). The follow-up rate varied by cancer stage at diagnosis, decreasing as stage increased (57% stage I vs 46% stage IV). (Table 1) . Overall, follow-up survey respondents reported significantly better function and lower symptom severity at baseline than those who were lost to follow-up.
Baseline characteristics of the participants who completed both a baseline and 6-month follow-up MYHealth survey (n 5 2968) and had supplemental medical record information (n 5 844) are provided in Table 1 . Most patients were aged 50 years (81%), and 53% of respondents were members of a racial/ethnic minority group. Although most participants were diagnosed with breast and prostate cancer, 7 different cancer types were represented in the sample, and 780 patients (26%) were diagnosed with advanced disease. One-half of participants reported "normal" performance status at baseline. The medical record participant subset reflects an intentional oversampling of patients with advanced-stage cancer (stage III/IV).
Overall, we observed that participants were largely unchanged or had small improvements across all measures over a 6-month period. Among the PROMIS symptom measures, we observed small declines in pain interference (mean change, 21.6; P < .001) and fatigue (mean change, 21.1; P < .001). Improvements were observed for physical function and social function (mean change, 0.8 and 1.1, respectively; P < .001 for both). An analysis of self-reported, 6-month, retrospective global change indicated that more participants reported improvement (a little or a lot) for pain (51%), fatigue (49%), anxiety (47%), and social function (44%). However, symptom increases/functional declines reported over this period were highest for fatigue (13%) and lowest for physical function (7%) ( Table 2) .
Across symptom and functional status, an answer of "a lot better/less" was associated with mean changes of 2 to 4 points (d range 5 0.22-0.44); "a little worse/more" was associated with mean changes of 3 to 6 points (d range 5 0.31-0.56); and "a lot worse" was associated with mean changes of 5 to 9 points (d range 5 0.53-0.72) ( Table 3 ). Mean PROMIS changes and effect sizes were larger for respondents who reported declines in function or worsening symptoms. For example, the mean change from baseline in the PROMIS fatigue score was 5.42 (d 5 0.62) among those who reported "a lot more fatigue" and 23.26 (d 5 0.38) among those who reported "a lot less fatigue" (Table 3 ). Depression and cognitive function measures were the most responsive to declines (8.5 and 8.7, respectively) and the least responsive to improvements (22.42 and 2.12, respectively) ( Table 3) . Patients who had a 1-point improvement on the ECOG PS had clinically meaningful (d 0.30) improvements on 5 PROMIS measures. Physical function had the largest improvement (mean change, 3.4 points; d 5 0.53), followed by pain (mean change, 24.5; d 5 0.45) ( Table 4 ). All measures were more sensitive to worsening performance status, with the largest change and effect size demonstrated for fatigue (mean change, 4.3; d 5 0.63). Data from our MRA cohort indicated that pain, fatigue, and depression were responsive to hospitalization, with reported mean score increases of 3 to 5 points and small-to-moderate effect sizes (fatigue, d 5 0.35; pain, 0.51; depression, 0.57). The correlation of change between the FACT-G Physical Well Being subscale ranged from r 5 0.33 (pain) to r 5 0.47 (fatigue) ( Table 5 ).
DISCUSSION
The current study provides support for the responsiveness of 8 PROMIS measures in a diverse cohort of patients with cancer, supporting past evaluations in cancer and other chronic conditions. 22 Most notably, our study supports and extends research findings from a study of patients with advanced-stage cancer in which a similar range for longitudinal anchor-based change was identified in PROMIS pain, fatigue, anxiety, depression, and physical function measures (d 5 0.36-0.67). 8 By using a larger, more diverse, national sample of patients with cancer, our findings provide evidence that a change of 3 to 5 points is sufficient across all PROMIS measures to identify clinically meaningful change.
This study also establishes that these PROMIS measures are responsive to functional recovery and symptom improvement in cancer. However, absolute changes in PROMIS scores tended to be smaller for patients who retrospectively reported a functional improvement/symptom decrease rather than for patients who reported a functional decline/symptom increase on global change ratings. This imbalance in change score magnitudes across retrospective 
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Cancer January 15, 2017 ratings of global health change has been reported in other cancer-specific PRO measures (ie, the FACT-G). 23 Despite attenuated responsiveness to retrospectively rated improvements, our study did demonstrate similar positive and negative responsiveness on PROMIS measures across a prospective assessment of change (patient-rated ECOG PS). Given the known methodological concerns using global retrospective change ratings (eg, recall bias, implicit evaluation of changes), our findings suggest prioritizing prospective change assessments in similar validation efforts.
These findings also present evidence that PROMIS measures are responsive to both medical and cancerspecific clinical events. We observed that a hospitalization within this 6-month period, between 6 and 18 months after diagnosis, was linked to clinically meaningful increases (range, 3-5 points) in pain, fatigue, and depression. This decline complements recent work examining the responsive of PROMIS measures in surgical recovery after heart transplantation. 7 Small increases in pain, fatigue, and sleep disturbance caused by a documented recurrence/ progression of cancer (range, 1.8-2.3 points) provide evidence of responsiveness to cancer-specific clinical events. In contrast, worsening in anxiety and depression was responsive only to patient self-reports of cancer at follow-up and was not based on clinical documentation alone. This difference suggests that anxiety and depression may be more sensitive to patient perception of recurrence or progression rather than clinical identification alone.
Limitations include the long time gap between ratings of change (6 months), which has been identified as creating difficulty in terms of obtaining accurate patient reports. 24 Nevertheless, the association between global ratings of change and actual change scores was reasonably high. MRA comparisons rely on a short period (6 months) to document recurrence/progression and, in some cases (hospitalization), report on very small samples. In addition, no further delineation was made to the 6-month window for evaluating patients after initial treatment, clinical events, or additional cancer-related treatments. Therefore, events could have occurred at any point within this 6-month period, potentially reducing the degree of responsiveness measured by the PROMIS short forms. Further research is necessary, and should focus on tracking the impact of cancer-specific medical events (eg, hospitalizations, adjuvant therapies, recurrence). Finally, it is possible that a scale recalibration-response shift might have occurred over the survey period, resulting in computed change scores that may not have been fully reflective of the true change that has taken place. However, the study was not designed to formally identify or evaluate this occurrence. These observational data provide a necessary first step in detailing sensitivity to change for 8 PROMIS measures when reported by cancer patients. They lay a ground work for incorporating the PROMIS measures into oncology clinical trials by helping inform sample size needs and power calculations for studies aimed at detecting a specific magnitude of change in 1 of these PRO endpoints. In addition, the data can help interpret the magnitude of change or differences in results observed with 1 or more PROMIS measures. These data also are timely, given the increased interest by the US Food and Drug Administration (FDA) in patient-focused drug development and the release of the FDA Clinical Outcomes Assessment Compendium to help guide applications to their Clinical Outcomes Assessment Qualification Program, as industry adoption of PROs increases. 25 Finally, although we have many cancer-specific PRO measures to choose from for use in cancer trials, few generic PRO measures have been validated with an appropriate degree of responsiveness in samples of patients who have cancer. These findings are among the first to indicate that PROMIS measures may be able to compare the magnitude of benefit or harm from treatments across both cancer and noncancer clinical trials (eg, for pain or symptom management studies or for measures of clinical benefit). This provides an opportunity to make meaningful comparisons across heath conditions and a broader context for the interpretation of PRO endpoints.
In conclusion, the current study presents strong evidence across multiple evaluation methods that PROMIS measures are responsive to both improvements and declines in symptoms and function experienced by patients with cancer. It extends past work, presenting further evidence that clinically meaningful changes across PROMIS measures range from 3 to 5 points. These results also highlight the utility using PROMIS measures in research (clinical trials, observational cohorts, and comparative effectiveness evaluations).
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